NDAORALTABLETPriority Review
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
3
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVISTA (raloxifene hydrochloride) is an oral selective estrogen receptor modulator (SERM) used primarily for the prevention and treatment of osteoporosis in postmenopausal women, and for reduction of breast cancer risk in high-risk populations. It mimics estrogen's beneficial effects on bone density while blocking estrogen effects in breast tissue.
$0.001BPart D
LOE ApproachingDeclining
Mature product in decline with modest Medicare utilization; commercial teams are likely focused on retention rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
Started Feb 2004
500 enrolled
Osteopenia
Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
Started Nov 1994
7,705 enrolled
Osteoporosis, Postmenopausal
EVA: Evista Alendronate Comparison
Osteoporosis
Career Relevance
EVISTA currently shows zero linked job postings, reflecting its mature LOE status and declining commercial focus. Career opportunities are limited and skewed toward defensive brand management, patient support programs, and regulatory compliance rather than growth-oriented roles.
Worked on EVISTA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.